| Virginia A Thurston, NP | |
|
613 Campus Dr, Suite 200, Abingdon, VA 24210-9703 | |
| (276) 628-1186 | |
| (276) 628-8507 |
| Full Name | Virginia A Thurston |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 613 Campus Dr, Abingdon, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043611882 | NPI | - | NPPES |
| Q009510 | Medicaid | TN | |
| P01440792 | Other | VA | RAILROAD MEDICARE |
| 1043611882 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 18819 (Tennessee) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 0024171725 (Virginia) | Primary |
| Entity Name | Blue Ridge Medical Management Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326159567 PECOS PAC ID: 9739099441 Enrollment ID: O20040715001336 |
News Archive
As the result of a six-year long research process, Fredrick R. Schumacher, PhD, a cancer epidemiology researcher at Case Western Reserve University School of Medicine, and an international team of more than 100 colleagues have identified 63 new genetic variations that could indicate higher risk of prostate cancer in men of European descent.
In the early 1990s, an international effort was launched by the U.S. Department of Energy and the National Institutes of Health to sequence the human genome. The project took 13 years, involved many scientists in several countries, and cost $2.7 billion (in FY 1991) dollars.
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
"X-rays can look alike, and if one patient's images are confused with another before the radiologist sees them, it can be difficult for the radiologist to determine there is a mismatch," said Dr. Srini Tridandapani, of Emory University and an author of the study.
› Verified 4 days ago
| Entity Name | Abingdon Physician Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306944350 PECOS PAC ID: 5991705667 Enrollment ID: O20070102000365 |
News Archive
As the result of a six-year long research process, Fredrick R. Schumacher, PhD, a cancer epidemiology researcher at Case Western Reserve University School of Medicine, and an international team of more than 100 colleagues have identified 63 new genetic variations that could indicate higher risk of prostate cancer in men of European descent.
In the early 1990s, an international effort was launched by the U.S. Department of Energy and the National Institutes of Health to sequence the human genome. The project took 13 years, involved many scientists in several countries, and cost $2.7 billion (in FY 1991) dollars.
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
"X-rays can look alike, and if one patient's images are confused with another before the radiologist sees them, it can be difficult for the radiologist to determine there is a mismatch," said Dr. Srini Tridandapani, of Emory University and an author of the study.
› Verified 4 days ago
| Entity Name | Highpower Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427329804 PECOS PAC ID: 5799945705 Enrollment ID: O20120329000194 |
News Archive
As the result of a six-year long research process, Fredrick R. Schumacher, PhD, a cancer epidemiology researcher at Case Western Reserve University School of Medicine, and an international team of more than 100 colleagues have identified 63 new genetic variations that could indicate higher risk of prostate cancer in men of European descent.
In the early 1990s, an international effort was launched by the U.S. Department of Energy and the National Institutes of Health to sequence the human genome. The project took 13 years, involved many scientists in several countries, and cost $2.7 billion (in FY 1991) dollars.
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
"X-rays can look alike, and if one patient's images are confused with another before the radiologist sees them, it can be difficult for the radiologist to determine there is a mismatch," said Dr. Srini Tridandapani, of Emory University and an author of the study.
› Verified 4 days ago
| Entity Name | Wellmont Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174808216 PECOS PAC ID: 8123291739 Enrollment ID: O20120627000467 |
News Archive
As the result of a six-year long research process, Fredrick R. Schumacher, PhD, a cancer epidemiology researcher at Case Western Reserve University School of Medicine, and an international team of more than 100 colleagues have identified 63 new genetic variations that could indicate higher risk of prostate cancer in men of European descent.
In the early 1990s, an international effort was launched by the U.S. Department of Energy and the National Institutes of Health to sequence the human genome. The project took 13 years, involved many scientists in several countries, and cost $2.7 billion (in FY 1991) dollars.
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
"X-rays can look alike, and if one patient's images are confused with another before the radiologist sees them, it can be difficult for the radiologist to determine there is a mismatch," said Dr. Srini Tridandapani, of Emory University and an author of the study.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Virginia A Thurston, NP 613 Campus Dr, Suite 200, Abingdon, VA 24210-9703 Ph: (276) 628-1186 | Virginia A Thurston, NP 613 Campus Dr, Suite 200, Abingdon, VA 24210-9703 Ph: (276) 628-1186 |
News Archive
As the result of a six-year long research process, Fredrick R. Schumacher, PhD, a cancer epidemiology researcher at Case Western Reserve University School of Medicine, and an international team of more than 100 colleagues have identified 63 new genetic variations that could indicate higher risk of prostate cancer in men of European descent.
In the early 1990s, an international effort was launched by the U.S. Department of Energy and the National Institutes of Health to sequence the human genome. The project took 13 years, involved many scientists in several countries, and cost $2.7 billion (in FY 1991) dollars.
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
"X-rays can look alike, and if one patient's images are confused with another before the radiologist sees them, it can be difficult for the radiologist to determine there is a mismatch," said Dr. Srini Tridandapani, of Emory University and an author of the study.
› Verified 4 days ago
Chesley Stanley, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 607 Campus Dr, Abingdon, VA 24210 Phone: 276-525-4603 | |
Matthew J Sykes, ANP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 300 East Valley Street, Abingdon, VA 24210 Phone: 276-628-7600 Fax: 276-628-2629 | |
Dr. Courtney Neel Rogers, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 16000 Johnston Memorial Dr Ste 213, Abingdon, VA 24211 Phone: 276-258-2600 | |
Rebekah Christine Davis, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 631 Campus Dr, Abingdon, VA 24210 Phone: 276-676-3870 Fax: 276-628-8927 | |
Mrs. Lora Diane Reynolds, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr, Suite 313, Abingdon, VA 24211 Phone: 276-258-3780 Fax: 276-258-3776 | |
Dr. Diana Michelle Oakes, DNP FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr Ste 312c, Abingdon, VA 24211 Phone: 276-258-1000 |